We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Sakura Finetek Europe B,V.

Sakura Finetek provides integrated solutions for anatomic pathology and patients to advance cancer diagnostics. The c... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Sakura Finetek Launches New Advanced Staining System

By LabMedica International staff writers
Posted on 06 Sep 2022
Print article
Image: Tissue-Tek Genie is the first and only fully automated, true random access stainer for IHC and ISH (Photo courtesy of Sakura Finetek)
Image: Tissue-Tek Genie is the first and only fully automated, true random access stainer for IHC and ISH (Photo courtesy of Sakura Finetek)

Sakura Finetek Europe (The Netherlands) has launched its newest solution Tissue-Tek Genie, an advanced staining system. The Tissue-Tek Genie Advanced Staining System is the first and only fully automated, true random access stainer for immunohistochemistry (IHC) and in situ hybridisation (ISH); thanks to its innovative technology makes it uncompromisingly fast, providing a predictable case turnaround time. With this groundbreaking system, the company enters a new market. The launch of Genie demonstrates the company’s commitment to supporting the provision of the next-generation immunohistochemistry solution.

By continuous 3rd-party clinical validation performed by NordiQC, Sakura Finetek provides optimal scoring antibodies only, focusing on the optimal result for pathologists and their patients. Tissue-Tek Genie is extending Sakura’s wide range of standardizing pre-analytical instruments. The company has a long history of technological innovations. Sakura Finetek had launched the first fully enclosed tissue processor: Tissue-Tek VIP, the first rapid tissue processor: Tissue-Tek Xpress and the first automated embedding system: Tissue-Tek AutoTEC. The Tissue-Tek Genie fits perfectly in that line and brings enormous opportunities for future innovations.

“I’m thrilled and proud with the launch of this innovative solution,” said Chris Koeman, President of Sakura Finetek Europe. “This underlines our company’s mission: empowering pathology professionals to deliver accurate and fast diagnoses to optimize treatment success for each life we touch.”

“This is a next-generation advanced staining system, a game changer in the complex world of advanced staining,” said Mateo Iglesias, Vice-President of Marketing and Sales. “Genie drives quality and standardization of every single slide, allowing our customers to make a confident diagnostic decision with a system that will guarantee consistent and optimal results.”

Related Links:
Sakura Finetek Europe 

New
Gold Supplier
Vaginosis Test
VAGINAL PANEL REALTIME PCR KIT
New
Portable Molecular Workstation
iPonatic III
New
Rapid Procalcitonin (PCT) Test
AQT90 FLEX PCT Assay
New
STI Test Kit
PlexPCR HSV-1&2, VZV

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Special blood test could determine if patient has early stage breast cancer and if the cancer is unlikely to return (Photo courtesy of USC)

Simple Blood Draw Could Revolutionize Early Breast Cancer Detection

Breast cancer is the most prevalent form of cancer in the world, affecting one in eight women over their lifetime. Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.